GlobeNewsWire
26 Mar 2026, 20:05 UTC · 25w ago
Verdict
Headline takes no side. We score IMDX +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Insight Molecular Diagnostics has submitted its GraftAssureDx assay to the FDA for regulatory review, with an expected authorization in 2026.
So whatFDA submission is a critical milestone for a development-stage company, transitioning the product toward a $2 billion addressable market.
More positive than 98% of claims this week
The company has engaged with 37 U.S. transplant centers, representing over 25% of all annual U.S. transplants.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 91% of claims this week
An independent head-to-head study presented at the CEoT conference showed favorable results for GraftAssureDx compared to a leading industry competitor.
So whatClinical superiority over competitors increases the likelihood of market share capture and regulatory success.
More positive than 85% of claims this week
Bio-Rad Laboratories has provided a fourth equity investment and ongoing technical support for the FDA submission.
So whatRepeated investment from a major industry player provides both financial runway and institutional validation of the technology.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company submitted its first kitted assay for FDA review, reported strong clinical interest from transplant centers, and shared favorable head-to-head study data.
More positive than 57% of ticker scores this week
Mentioned as a strategic partner and equity investor providing critical scientific and financial support to iMDx.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−2.7%
Price is moving against the score
$4.00 vs $4.11 close before publication (Mar 26) · not market-adjusted
IMDX chart →
